Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 6
2004 1
2006 3
2007 1
2008 1
2009 7
2010 10
2011 11
2012 10
2013 6
2014 7
2015 7
2016 3
2017 7
2018 5
2019 6
2020 6
2021 6
2022 11
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Results by year

Filters applied: . Clear all
Page 1
Phase 3 Trial of Concizumab in Hemophilia with Inhibitors.
Matsushita T, Shapiro A, Abraham A, Angchaisuksiri P, Castaman G, Cepo K, d'Oiron R, Frei-Jones M, Goh AS, Haaning J, Hald Jacobsen S, Mahlangu J, Mathias M, Nogami K, Skovgaard Rasmussen J, Stasyshyn O, Tran H, Vilchevska K, Villarreal Martinez L, Windyga J, You CW, Zozulya N, Zulfikar B, Jiménez-Yuste V; explorer7 Investigators. Matsushita T, et al. N Engl J Med. 2023 Aug 31;389(9):783-794. doi: 10.1056/NEJMoa2216455. N Engl J Med. 2023. PMID: 37646676 Clinical Trial.
MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting.
Pomella S, Cassandri M, D'Archivio L, Porrazzo A, Cossetti C, Phelps D, Perrone C, Pezzella M, Cardinale A, Wachtel M, Aloisi S, Milewski D, Colletti M, Sreenivas P, Walters ZS, Barillari G, Di Giannatale A, Milano GM, De Stefanis C, Alaggio R, Rodriguez-Rodriguez S, Carlesso N, Vakoc CR, Velardi E, Schafer BW, Guccione E, Gatz SA, Wasti A, Yohe M, Ignatius M, Quintarelli C, Shipley J, Miele L, Khan J, Houghton PJ, Marampon F, Gryder BE, De Angelis B, Locatelli F, Rota R. Pomella S, et al. Among authors: barillari g. Nat Commun. 2023 Dec 15;14(1):8373. doi: 10.1038/s41467-023-44130-0. Nat Commun. 2023. PMID: 38102140 Free PMC article.
Translational Implications for Radiosensitizing Strategies in Rhabdomyosarcoma.
Pomella S, Porrazzo A, Cassandri M, Camero S, Codenotti S, Milazzo L, Vulcano F, Barillari G, Cenci G, Marchese C, Fanzani A, Megiorni F, Rota R, Marampon F. Pomella S, et al. Among authors: barillari g. Int J Mol Sci. 2022 Oct 31;23(21):13281. doi: 10.3390/ijms232113281. Int J Mol Sci. 2022. PMID: 36362070 Free PMC article. Review.
Radioresistance in rhabdomyosarcomas: Much more than a question of dose.
Camero S, Cassandri M, Pomella S, Milazzo L, Vulcano F, Porrazzo A, Barillari G, Marchese C, Codenotti S, Tomaciello M, Rota R, Fanzani A, Megiorni F, Marampon F. Camero S, et al. Among authors: barillari g. Front Oncol. 2022 Sep 29;12:1016894. doi: 10.3389/fonc.2022.1016894. eCollection 2022. Front Oncol. 2022. PMID: 36248991 Free PMC article. Review.
Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma.
Lucarini V, Melaiu O, D'Amico S, Pastorino F, Tempora P, Scarsella M, Pezzullo M, De Ninno A, D'Oria V, Cilli M, Emionite L, Infante P, Di Marcotullio L, De Ioris MA, Barillari G, Alaggio R, Businaro L, Ponzoni M, Locatelli F, Fruci D. Lucarini V, et al. Among authors: barillari g. J Exp Clin Cancer Res. 2022 Nov 17;41(1):326. doi: 10.1186/s13046-022-02525-9. J Exp Clin Cancer Res. 2022. PMID: 36397148 Free PMC article.
Pharmacological management of Kaposi's sarcoma.
Sgadari C, Bacigalupo I, Barillari G, Ensoli B. Sgadari C, et al. Among authors: barillari g. Expert Opin Pharmacother. 2011 Aug;12(11):1669-90. doi: 10.1517/14656566.2011.577066. Epub 2011 Apr 25. Expert Opin Pharmacother. 2011. PMID: 21517697 Review.
The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies.
Melaiu O, Vanni G, Portarena I, Pistolese CA, Anemona L, Pomella S, Bei R, Buonomo OC, Roselli M, Mauriello A, Barillari G. Melaiu O, et al. Among authors: barillari g. Int J Mol Sci. 2023 Feb 6;24(4):3226. doi: 10.3390/ijms24043226. Int J Mol Sci. 2023. PMID: 36834641 Free PMC article. Review.
115 results